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CASE REPORT
Abstract: An adolescent with Hurler-Scheie syndrome is reported. This now 15 year-old-
young woman was initially diagnosed at age 4. She was assessed for neurocognitive functioning
at ages 5, 13, and 15 years. Results show a significant decline in intellectual functioning from
the superior range to the average range from age 5 to age 13, and then no change from age 13
to age 15. The relationship between Hurler-Scheie syndrome, premorbid intellectual
functioning, and cognitive–behavioral interventions are discussed in light of the longitudinal
neurocognitive effects of this disease.
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Introduction
The mucopolysaccharidoses (MPS) are a family of genetic disorders characterized
by changes in an individual’s ability to metabolize mucopolysaccharides, which are
complex sugar molecules found in the connective tissue, mucosal fluids, synovial
fluid, and other cells throughout the body. There are six types of MPS, with some
types having several subtypes. According to Brown (1999), epidemiological data
are problematic to report, but range from 1 in 100 000 live births to 1 in 600 000 live
births. This dysfunction in metabolism may result in a variety of distinct physical
features, such as short stature, contracture of joints, claw-like hands, abnormal spine
curvature, and hydrocephalus (Neufeld and Muenzer 1995). Treatment options vary,
but hematopoietic cell transplantation seems to offer the best long-term quality of
life improvement and decreased mortality and morbidity options for children with
some of the more severe forms of MPS (Grewal et al 2002).
One subtype of MPS is MPS I, which includes Hurler, Scheie, and Hurler-Scheie
syndromes. Each of these disorders within MPS I is caused by a deficiency of alpha-
L-iduronidase. Within MPS I, Hurler syndrome is generally associated with more
severe features and poorer prognosis than either Scheie or Hurler-Scheie syndromes
(Brown 1999). In most cases of Hurler syndrome, motor skills are limited by age 18
months, and developmental regression occurs, including progressive loss of
neurocognitive functioning, resulting in mental retardation. With Hurler-Scheie
syndrome, these declines usually appear between 3 and 8 years of age, with milder
neurocognitive losses and a low risk for early mortality. These neurocognitive losses
typically include progressive dementia resulting from hydrocephalus and increasing
deposits of nonmetabolized mucopolysaccharides (Shapiro et al 1995). Language
and memory deficits after a period of initial developmental slowing have been
associated with the more severe forms of MPS I (Guffon et al 1998).
While neurocognitive deficits have been associated with MPS, to date there are
few neurocognitive reports of children with this disorder and no longitudinal studies,
resulting in scant knowledge regarding appropriate assessment and intervention
(Brown 1999). Many studies report cross-sectional assessments of these children at
different stages. In this case report, we have the opportunity to follow a young lady
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with Hurler-Scheie syndrome over the course of 10 years,
documenting the quantity and quality of neurocognitive
effects associated with this disease. This represents a rare
chance to longitudinally track the effects of Hurler-Scheie
in a young person and allows recommendations to be made
to health care professionals regarding potential
neurocognitive and psychological care for children with this
disorder.
Researchers are currently engaging in novel therapies
designed to reduce and perhaps reverse the effects of Hurler-
Scheie. However, while these therapies may have a
beneficial effect on orthopedic, skeletal, or ophthalamic
problems, their effect on neurocognitive functioning is not
clearly understood. Thus, we are in a position to begin
documenting both the physiological and neurocognitive
effects of these new treatments. The focus of this case report
is to describe long-term neurocognitive changes in a young
female with Hurler-Scheie syndrome that was treated
using enzyme replacement therapy. To our knowledge,
this is the first longitudinal case report of a patient
receiving enzyme replacement therapy for Hurler-Scheie
syndrome.
Case report
The following information was collected with the approval
of the Institutional Review Board at the University of
Mississippi Medical Center. Written consent was obtained
from both the patient and her parent. We report the case of
a now 15-year-old female diagnosed with MPS-I,
specifically Hurler-Scheie syndrome, Alpha (not her real
name). Alpha’s mother gave consent for her child to serve
as a subject in this investigation, and Alpha gave assent.
Alpha was the product of a normal pregnancy, labor, and
delivery. Family history is negative for known
neuromuscular or metabolic disorders. Her parents are both
college-educated professionals. Her mother reported Alpha
grew well at first, but then seemed to “slow down.” Her
mother also noted Alpha could not raise her arms over her
head, even as an infant. At age 3.5 years, Alpha complained
of wrist pain, and was seen by her primary care physician.
Alpha began taking gymnastics class as part of her 4-year-
old preschool; her instructor noted that Alpha could not
touch her toes or raise her arms.
Alpha was then referred to a local orthopedic clinic and
x-rays were obtained. According to Alpha’s mother, the
clinic noted “something wrong” on the x-ray films, and
referred Alpha to a pediatric orthopedic surgeon for further
evaluation. The surgeon noted that Alpha had no scoliosis.
Alpha could not actively abduct her shoulders beyond 90
degrees and passive abduction was limited to 130 degrees.
She was noted to have good finger function and grip, and a
full range of motion in her neck, hips, knees, ankles, and
elbows, with no appreciable organomegaly. The initial
diagnosis considered was arthrogryposis. However, after
reviewing the x-rays and noting atypical features such as
broad ribs with some notching at the medial metaphyseal
ends, and smaller than usual femoral heads bilaterally, the
orthopedic surgeon suspected Alpha had Scheie syndrome,
one of the MPS I syndromes. Alpha was referred to a
geneticist to conduct urine and blood tests and was diagnosed
with Hurler-Scheie syndrome.
By age 8, Alpha remained a very happy, bright young
lady who was active in theatre camp and swimming (she
used her own, special technique according to her mother).
She could actively abduct her shoulders 80 degrees and had
about 50% range of motion in her neck. She was wearing
glasses, was an avid reader, and was doing very well in
school.
By age 10 in 1999, Alpha was 50 inches (124 cm) tall
and weighed 71 pounds (32 kg). She had restricted range of
motion in her hips and knees, and was beginning to complain
of neck pain.
In 2000, at the age of 12, Alpha was admitted for the
placement of a VP shunt secondary to increasing
hydrocephalus. She currently maintains this shunt, with no
complications. She also began enzyme replacement therapy
in 2000 on a pharmaceutical study at the age of 12, as well
as outpatient physical therapy to encourage range of motion
in her extremities. Her physical condition improved, so that
she had better range of motion. Tanner staging was noted
as appropriate for her age; in general, Hurler-Scheie and
Scheie patients have normal puberty and reproductive
abilities. She has strong family support and appropriate
expectations for her future.
Her neurocognitive functioning was assessed three times,
in June 1994 when she was 5 years 11 months old, in June
2002 when she was 13 years 11 months old, and in July
2003, when she was 15 years old. The initial assessment at
age 5–11 was not conducted by the authors, but took place
at another location. However, this assessment was done by
a licensed clinical psychologist who used age-appropriate,
valid measures. Copies of the report from that assessment
were reviewed from the patient’s medical chart.
Given her young age (5–11) at her initial assessment,
the patient was administered the Stanford-Binet Intelligence
Scale, Fourth Edition, and the Wide Range AchievementNeuropsychiatric Disease and Treatment 2006:2(3) 383
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Test, Third Edition (see Table 1). These measures assess for
intelligence (IQ) and achievement, respectively. At the time,
the patient had just completed kindergarten, had no behavior
problems, and was considered by her teachers to be ready
for the first grade. Her mother likewise thought the patient
was doing well academically, but was concerned that the
patient could perhaps have been showing signs of mild
forgetfulness. Overall, the scores on these measures range
from the average to the highly superior range, as she scored
at or above the 90th percentile in most areas. At that time, it
was clear that Alpha was functioning in the average to
superior range intellectually and academically, and had no
significant behavioral or emotional problems.
Alpha’s parents were aware of the impressive nature of
these findings, but were also aware of the usual course of
this disease, including gradual neurocognitive decline. They
began both systematic and non-specific interventions
designed to challenge Alpha intellectually and stimulate her
already significant cognitive abilities. These included
summer camps, art classes, and music lessons. Alpha was
enrolled in a school that stressed academic excellence, and
her mother reported that Alpha did well through the seventh
grade. Alpha was home-schooled for the second half of the
seventh grade, as she was travelling frequently to receive
treatment for her condition. When she began eighth grade
back at her same school, her grades began to fall from
consistent As up through the seventh grade to Bs and Cs in
the eighth grade. This prompted Alpha’s parents to seek
another neurocognitive evaluation.
At the time of the second assessment, the patient was 13
years and 11 months, and so could complete a more
comprehensive neurocognitive battery (see Table 2). This
second battery consisted of parts of the Wechsler Intelligence
Scale for Children – Third Edition (WISC-III), Woodcock-
Johnson Tests of Cognitive Ability – Third Edition (WJ-
III), the Wide Range Assessment of Memory and Learning
(WRAML), the California Verbal Learning Test – Children’s
Version (CVLT-C), the Stroop Color and Word Test, the Rey-
Osterrieth Complex Figure Test (ROCF), the Child Behavior
Checklist (CBCL-parent report), the Youth Self Report
(YSR), the Children’s Depression Inventory (CDI), and the
Revised Children’s Anxiety and Depression Scale
(RCADS). This battery is designed to be a comprehensive
measure of intelligence, neurocognitive functioning, and
behavioral and emotional adjustment. It should be noted
that though different batteries of measures were used
between neurocognitive assessments, the results from both
assessments are comparable. Specifically, overall
intelligence quotient (IQ) scores between the Stanford-Binet
and the Woodcock-Johnson show good correlation (Sattler
1992).
Results from this second assessment indicate a
significant decline in overall abilities from Alpha’s initial
level of functioning. Her abilities were now within the
average range of functioning; however, she again
demonstrated no significant behavioral or emotional
problems. Alpha’s parents began implementing suggested
interventions, including after school tutoring and structuring
Alpha’s study time so that she studied for short blocks of
time with frequent breaks. At the time of this report, Alpha’s
mother described Alpha as doing better in school (generally
Bs and Cs, a few As), and continuing to be emotionally and
socially well-adjusted.
Alpha completed her third assessment battery
approximately one year later at age 15–0. She completed
the same battery as the one she completed at age 13–11 (see
Table 3). This third assessment demonstrated no further
decline in intellectual functioning from the second
assessment. As before, no behavioral or emotional
difficulties were reported.
Table 1 Initial evaluation, age 5–11
Measure Subtest Standard score Percentile Range
Stanford-Binet
M=100, SD=16 Composite (IQ) 121 91 Superior
Verbal reasoning 112 77 High average
Abstract-visual reasoning 140 99 Very superior
Quantitative reasoning 116 84 High average
Short-term memory 102 55 Average
Wide range achievement test
M=100, SD=15 Reading 123 94 Superior
Spelling 120 91 Superior
Arithmetic 121 92 SuperiorNeuropsychiatric Disease and Treatment 2006:2(3) 384
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Discussion
While declines in neurocognitive functioning are generally
expected in children with MPS, this case report of a young
lady with Hurler-Scheie demonstrates that declines may
proceed at different rates and are likely influenced by
premorbid neurocognitive functioning and environmental–
behavioral vectors. In other words, Alpha’s current level of
“average” neurocognitive functioning is probably the result
of impressive capabilities prior to the onset of Hurler’s
syndrome as well as the degree of intervention and cognitive
expectations that characterize her family system. The idea
of cognitive reserve as a protective factor in individuals who
have some sort of neurological insult has been assumed in
children with traumatic brain injury and brain tumors. Thus,
it could be that since Alpha had such a high premorbid level
of functioning, she had more to “spare” during the course
of her illness and treatment (Taylor 2004). It should be noted
that many children with Hurler-Scheie show some degree
of cognitive sparing, in comparison with other types of MPS.
However, this sparing is remarkable for its robustness. Also,
biological factors should be considered as influencing these
findings. It should be noted that Alpha has been diagnosed
with a milder form of MPS, Hurler-Scheie, and that this
subtype of MPS has been shown to involve relative
neurocognitive sparing (Brown 1999). However, this report
is the first of its kind to our knowledge to document
longitudinal changes in a youngster.
The issue of Alpha’s current level of neurocognitive
functioning cannot be fully addressed in this report. Her
initial decline is undoubtedly related to her diagnosis of
Hurler-Scheie syndrome. However, the amount of decline
and conversely the degree of neurocognitive sparing
attributable to her premorbid functioning and behavioral
interventions by her parents is indeterminable. The
differences in her test performance may be attributable to
regression to the mean, a common result of multiple
assessments conducted on a single individual. Consequently,
we cannot estimate the amount of variance accounted for
by Alpha’s premorbid intellectual capabilities, Hurler-Scheie
syndrome, and her parents’ level of cognitive and intellectual
interventions. It should also be noted that the measured
decline in IQ might be related to progressive motor
Table 2 Second evaluation, age 13–11
Measure Subtest Standard score Percentile Range
WJ-III
M=100, SD=15 General intellectual ability (IQ) 100 50 Average
Verbal ability 104 61 Average
Thinking ability 100 49 Average
Cognitive efficiency 95 37 Average
Phonemic awareness 102 55 Average
Working memory 97 42 Average
WISC-III
M=10, SD=3 Spatial span 13 High average
WRAML
M=10, SD=3 Visual learning 7 Low average
CVLT-C
M=0.0, SD=1.0 List A trial 1 free recall 0.0 Average
List A trial 5 free recall 0.5 Average
List B free recall –0.5 Average
Semantic clustering 2.5 Superior
Serial clustering –1.0 Low average
Recognition 0.0 Average
ROCF
M=10, SD=3 Copy 12 75 Average
Immediate recall 13 100 Superior
Delayed recall 13 100 Superior
Stroop
M=100, SD=15 Word score 95 Average
Color score 91 Average
Color-word score 100 Average
Interference 107 Average
Abbreviations: CVLT-C, California Verbal Learning Test – Children’s Version; ROCF, Rey-Osterrieth Complex Figure Test; WISC-III, Wechsler Intelligence Scale for
Children – Third Edition; WJ-III, Woodcock-Johnson Tests of Cognitive Ability – Third Edition; WRAML, Wide Range Assessment of Memory and Learning.Neuropsychiatric Disease and Treatment 2006:2(3) 385
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dysfunction, as this might affect some of the subtests on the
neurocognitive measures. There are no reports of the
possible neurocognitive-sparing or –improving effects of
enzyme replacement therapy, which Alpha received. Further
research in this area is warranted.
Weaknesses of this case report include the use of
different measures of intelligence and neurocognitive
functioning. However, all measures used to assess this
patient are well-established, well-validated measures, and
hence should be interpreted as adequately reflecting her level
of neurocognitive functioning at the time they were
administered.
Conclusion
This case represents a unique opportunity to study a genetic
disorder with neurocognitive effects, in the light of
apparently strong biological and environmental protective
factors. Children with Hurler-Scheie syndrome should be
followed regularly with neurocognitive assessments in order
both to document expected intellectual declines and to target
areas for cognitive and behavioral interventions that might
slow the decline associated with this disease. The strong
behavioral and environmental support that Alpha received
from her parents cannot be discounted. Alpha’s parents
proactively began working with her in light of her diagnosis,
and then followed through with a neurocognitive
rehabilitation plan suggested by the first author (TDE). This
neurocognitive rehabilitation plan was tailored to address
the specific levels of functioning that Alpha evidenced from
her assessments.
We strongly recommend neurocognitive assessment and
intervention for these patients, alongside newer medical
interventions. The lack of continued neurocognitive decline
from age 13–11 to age 15–0 may be attributable to (1) the
milder form of MPS with which Alpha was diagnosed, (2)
the newer treatments initiated by the team of physicians
(JM), (3) the fact that Alpha probably began life with a
higher-than-average neurocognitive capacity, or (4) the
supportive and appropriately challenging environment of
social support that Alpha enjoyed. Undoubtedly, all four of
these factors are inter-related. However, neurocognitive
assessment adds a low burden to an overall treatment plan,
and can help with behavioral interventions designed to
improve long-term neurocognitive functioning.
Table 3 Third evaluation, age 15–0
Measure Subtest Standard score Percentile Range
WJ-III
M=100, SD=15 General intellectual ability (IQ) 101 54 Average
Verbal ability 98 44 Average
Thinking ability 98 46 Average
Cognitive efficiency 108 70 Average
Phonemic awareness 112 79 Average
Working memory 100 49 Average
WISC-III
M=10, SD=3 Spatial span 13 High average
WRAML
M=10, SD=3 Visual learning 6 Low average
CVLT-C
M=0.0, SD=1.0 List A trial 1 free recall 1.0 Average
List A trial 5 free recall 1.0 Average
List B free recall 0.0 Average
Semantic clustering 3.0 Superior
Serial clustering –1.0 Low average
Recognition 0.0 Average
ROCF
M=10, SD=3 Copy 13 100 Average
Immediate recall 13 100 Superior
Delayed recall 12 75 Superior
Stroop
M=100, SD=15 Word score 92 Average
Color score 91 Average
Color-word score 111 Average
Interference 117 HighAverage
Abbreviations: CVLT-C, California Verbal Learning Test – Children’s Version; ROCF, Rey-Osterrieth Complex Figure Test; WISC-III, Wechsler Intelligence Scale for
Children – Third Edition; WJ-III, Woodcock-Johnson Tests of Cognitive Ability – Third Edition; WRAML, Wide Range Assessment of Memory and Learning.Neuropsychiatric Disease and Treatment 2006:2(3) 386
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